Quinton Oswald, President/CEO Neurotech Pharmaceuticals, Inc.  Questions regarding the efficacy, tolerability, and best practices for long-term VEGF suppression in AMD patients continue to plague conventional bolus injection- based approaches to wet AMD treatment. A well-tolerated, implantable encapsulated cell line engineered to generate and release therapeutic molecules into the vitreous would change all that, and its advent may be closer than many think.